Company: LHI
Filing Date: 2025-05-23
Form Type: F-1
Source: 0001213900-25-046955
Chunk: 52

Company: Living Homeopathy International Ltd.
Filing Date: 2025-05-23
Form: F-1
Chunk 52
---
. You may be unable to remove a director of the Company.

A director of the Company is not subject to a term of office and shall
hold office until he or she is removed or resigned in accordance with our Amended and Restated Memorandum and Articles of Association,
unless such director is appointed on such express terms that he or she shall automatically retire from office (unless he or she has sooner
vacated office) at the next or a subsequent annual general meeting or upon any specified event or after any specified period. According
to our Amended and Restated Memorandum and Articles of Association, a director may be removed by an ordinary resolution of our shareholders.
An ordinary resolution to be passed at a general meeting of the shareholders requires the affirmative vote of a simple majority of all
votes which are cast by those shareholders entitled to vote who are present in person or by proxy at such general meeting. Immediately
after the offering, the two Class B shareholders, consisting of LTO Holdings Ltd. and Qingtian Holdings Ltd, will own an aggregate of
8,500,000 ordinary shares, consisting of 7,500,000 Class A Ordinary Shares and 1,000,000 Class B Ordinary Shares, representing 89.11%
of our total voting power of our outstanding ordinary shares. In cases where their interests are aligned and they vote together, they
could control the outcome of the matters submitted to shareholders for approval, including the removal of any of the directors. Therefore,
if the two Class B shareholders vote together against the removal of any director, you may not be able to remove such director.

Living Homeopathy’s lack of effective internal controls over financial reporting may affect its ability to accurately report its financial results or prevent fraud, which may affect the market for and price of Living Homeopathy’s Class A Ordinary Shares.

To implement Section 404 of the Sarbanes-Oxley Act of 2002, the SEC adopted rules requiring public companies to include a report of management on the company’s internal control over financial reporting. Prior to filing the registration statement of which this prospectus is a part, Living Homeopathy was a private company with limited accounting personnel and other resources for addressing Living Homeopathy’s internal control over financial reporting. Living Homeopathy’s management has not completed an assessment of the effectiveness of Living Homeopathy’s internal control over financial reporting and its independent registered public accounting firm has not conducted an audit of Living Homeopathy’s internal control over financial reporting.

<div align='center'>27</div>

Living Homeopathy will be